Protagonist Therapeutics, Inc - Common Stock (PTGX)
CUSIP: 74366E102
Q4 2025 13F Holders as of 31 Dec 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 62,457,444
- Total 13F shares
- 70,709,233
- Share change
- -562,363
- Total reported value
- $6,175,381,025
- Put/Call ratio
- 5.8%
- Price per share
- $87.34
- Number of holders
- 310
- Value change
- +$99,663,953
- Number of buys
- 160
- Number of sells
- 143
Quarterly Holders Quick Answers
What is CUSIP 74366E102?
CUSIP 74366E102 identifies PTGX - Protagonist Therapeutics, Inc - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 74366E102:
Top shareholders of PTGX - Protagonist Therapeutics, Inc - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock, Inc. |
13F
13D/G
|
Company |
14%
from 13D/G
|
9,404,232
|
$624,723,149 | — | 30 Sep 2025 | |
| Farallon Capital Partners, L.P. |
13D/G
|
Dapice Joshua J. |
10%
|
6,248,013
|
$545,701,455 | +$25,461,794 | 31 Dec 2025 | |
| FARALLON CAPITAL MANAGEMENT LLC |
13F
|
Company |
9.9%
|
6,196,006
|
$411,600,679 | — | 30 Sep 2025 | |
| RTW INVESTMENTS, LP |
13D/G
13F
|
Company |
8.1%
|
5,059,053
|
$405,989,003 | $0 | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
6.8%
|
4,257,229
|
$282,807,724 | — | 30 Sep 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13D/G
13F
|
Company |
5.1%
|
3,171,423
|
$254,506,696 | $0 | 31 Dec 2025 | |
| STATE STREET CORP |
13F
13D/G
|
Company · STATE STREET CORPORATION |
5.2%
from 13D/G
|
3,165,795
|
$210,303,762 | — | 30 Sep 2025 | |
| BVF INC/IL |
13F
|
Company |
4.1%
|
2,560,916
|
$170,121,650 | — | 30 Sep 2025 | |
| BIOTECHNOLOGY VALUE FUND L P |
13D/G
|
BVF PARTNERS L P/IL |
4.1%
|
2,560,916
|
$170,121,650 | -$43,187,804 | 30 Sep 2025 | |
| JOHNSON & JOHNSON |
13F
|
Company |
3.9%
|
2,449,183
|
$162,699,227 | — | 30 Sep 2025 | |
| UBS Group AG |
13F
|
Company |
3%
|
1,896,008
|
$125,951,812 | — | 30 Sep 2025 | |
| Deep Track Capital, LP |
13D/G
13F
|
Company |
2.8%
|
1,715,691
|
$113,973,353 | -$101,924,147 | 30 Sep 2025 | |
| Woodline Partners LP |
13F
|
Company |
2.3%
|
1,438,247
|
$95,542,748 | — | 30 Sep 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2.3%
|
1,416,646
|
$94,122,036 | — | 30 Sep 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
2%
|
1,220,436
|
$81,075,000 | — | 30 Sep 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.8%
|
1,139,854
|
$75,720,501 | — | 30 Sep 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
1.8%
|
1,100,821
|
$73,165,449 | — | 30 Sep 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
1.7%
|
1,085,564
|
$72,114,017 | — | 30 Sep 2025 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
1.6%
|
1,030,134
|
$68,431,802 | — | 30 Sep 2025 | |
| Commodore Capital LP |
13F
|
Company |
1.6%
|
1,025,000
|
$68,090,750 | — | 30 Sep 2025 | |
| Invesco Ltd. |
13F
|
Company |
1.6%
|
1,003,706
|
$66,676,188 | — | 30 Sep 2025 | |
| ADAR1 Capital Management, LLC |
13F
|
Company |
1.6%
|
989,182
|
$65,711,360 | — | 30 Sep 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.3%
|
829,877
|
$55,128,729 | — | 30 Sep 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.3%
|
822,212
|
$54,619,543 | — | 30 Sep 2025 | |
| Jefferies Financial Group Inc. |
13F
|
Company |
1.3%
|
821,503
|
$54,572,444 | — | 30 Sep 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.3%
|
781,711
|
$51,929,062 | — | 30 Sep 2025 | |
| MORGAN STANLEY |
13F
|
Company |
1.2%
|
768,359
|
$51,042,146 | — | 30 Sep 2025 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
1.1%
|
718,202
|
$47,710,159 | — | 30 Sep 2025 | |
| Lynx1 Capital Management LP |
13F
|
Company |
1.1%
|
700,014
|
$46,501,930 | — | 30 Sep 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.97%
|
603,222
|
$40,072,039 | — | 30 Sep 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.96%
|
600,047
|
$39,861,248 | — | 30 Sep 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.89%
|
552,877
|
$36,727,619 | — | 30 Sep 2025 | |
| FMR LLC |
13F
|
Company |
0.83%
|
520,664
|
$34,587,709 | — | 30 Sep 2025 | |
| MANGROVE PARTNERS IM, LLC |
13F
|
Company |
0.77%
|
478,413
|
$31,780,976 | — | 30 Sep 2025 | |
| BNP Paribas Asset Management Holding S.A. |
13F
|
Company |
0.72%
|
451,766
|
$30,011,000 | — | 30 Sep 2025 | |
| Focus Partners Wealth |
13F
|
Company |
0.72%
|
448,988
|
$29,826,273 | — | 30 Sep 2025 | |
| TORONTO DOMINION BANK |
13F
|
Company |
0.71%
|
445,440
|
$29,590,579 | — | 30 Sep 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.7%
|
438,515
|
$29,127,247 | — | 30 Sep 2025 | |
| 683 Capital Management, LLC |
13F
|
Company |
0.65%
|
407,500
|
$27,070,225 | — | 30 Sep 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.58%
|
363,261
|
$24,131,429 | — | 30 Sep 2025 | |
| PRINCIPAL FINANCIAL GROUP INC |
13F
|
Company |
0.52%
|
326,088
|
$21,662,027 | — | 30 Sep 2025 | |
| VOYA INVESTMENT MANAGEMENT LLC |
13F
|
Company |
0.49%
|
305,419
|
$20,288,984 | — | 30 Sep 2025 | |
| Logos Global Management LP |
13F
|
Company |
0.48%
|
300,000
|
$19,929,000 | — | 30 Sep 2025 | |
| RAYMOND JAMES FINANCIAL INC |
13F
|
Company |
0.47%
|
294,296
|
$19,550,084 | — | 30 Sep 2025 | |
| ALLIANCEBERNSTEIN L.P. |
13F
|
Company |
0.42%
|
260,854
|
$17,328,531 | — | 30 Sep 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.4%
|
252,400
|
$16,766,932 | — | 30 Sep 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
0.38%
|
237,881
|
$15,802,435 | — | 30 Sep 2025 | |
| PUBLIC SECTOR PENSION INVESTMENT BOARD |
13F
|
Company |
0.37%
|
228,146
|
$15,155,739 | — | 30 Sep 2025 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.35%
|
220,600
|
$14,654,458 | — | 30 Sep 2025 | |
| KENNEDY CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.33%
|
208,437
|
$13,846,470 | — | 30 Sep 2025 |
Institutional Holders of Protagonist Therapeutics, Inc - Common Stock (PTGX) as of Q4 2025
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q4 2025 vs Q3 2025 Across Filers
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 Value $ | Q4 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
An asterisk sign (*) next to the price indicates that the price is likely invalid.